Amicus Therapeutics Inc. (FOLD)

FOLD (NASDAQ:Biotechnology) EQUITY
neg -0.04
Today's Range: 14.85 - 15.56 | FOLD Avg Daily Volume: 2,623,200
Last Update: 02/22/18 - 4:00 PM EST
Volume: 4,230,558
YTD Performance: 3.13%
Open: $15.26
Previous Close: $15.12
52 Week Range: $5.87 - $17.40
Oustanding Shares: 166,269,000
Market Cap: 2,522,300,781
6-Month Chart
TheStreet Ratings Grade for FOLD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.00 1.00 1.00 1.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -7.98
Price Earnings Comparisons:
FOLD Sector Avg. S&P 500
-7.98 0.00 23.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.33% 141.15% 70.57%
Revenue 0.00 12.70 1.37
Net Income 24.17 2.40 0.00
EPS 24.17 0.30 0.00
Earnings for FOLD:
Revenue 0.00B
Average Earnings Estimates
Qtr (12/17) Qtr (03/18) FY (12/17) FY (12/18)
Average Estimate $-0.30 $-0.30 $-1.51 $-1.13
Number of Analysts 5 2 6 6
High Estimate $-0.23 $-0.28 $-1.18 $-0.90
Low Estimate $-0.39 $-0.32 $-1.76 $-1.65
Prior Year $-0.32 $-0.39 $-1.39 $-1.51
Growth Rate (Year over Year) 6.87% 23.08% -8.75% 25.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Markets have weakened over the past hour. There has been a very narrow trading range so far today. Biotech continued to strengthen. I think the sector is gaining a bit of strength as some small caps like Amicus Therapeutics (FOLD)  present at the JP Morgan Healthcare conference in San Francisco and received favorable reviews.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
Looking for a good stock? Find a good chart pattern.
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
So I'm staying focused on stock picking.
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Columnist Conversations

Short-term signals have been quite good recently. No short term overbought conditions are in place at this ti...
Stericycle (SRCL) came in shy of estimates for the fourth quarter. The stock has been crushed. As of 11:17 AM...
Join me for a free webinar later today with my Real Money colleague and good friend Toni Turner.  Toni is...
Just off the horn with Roku's (ROKU) CFO -- he still seemed darn upbeat on the story to me. Even still, will ...


News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.